Angelalign Elevates Chairman Feng Dai to Executive Role as Board Reshapes for Global Push

Angelalign Technology Inc. ( (HK:6699) ) has provided an update.

Angelalign Technology has re-designated long-serving board chairman Feng Dai from non-executive to executive director, effective 23 April 2026, positioning him as executive chairman with primary responsibility for strategy, corporate governance, risk management and business development. The move leverages Feng’s extensive global medical device and investment background, including his leadership at oral health-focused CareCapital Advisors, to reinforce the group’s capabilities in critical functions and support sustainable growth.

Separately, director Song Xin has resigned from the board, also effective 23 April 2026, while remaining chief strategy officer to continue steering the company’s strategic agenda off-board. The board emphasized its intention to further internationalize its composition in line with Angelalign’s growing global presence, a governance shift that may enhance strategic agility and broaden perspectives for stakeholders as the company deepens its reach in worldwide oral health markets.

The most recent analyst rating on (HK:6699) stock is a Buy with a HK$91.89 price target. To see the full list of analyst forecasts on Angelalign Technology Inc. stock, see the HK:6699 Stock Forecast page.

More about Angelalign Technology Inc.

Angelalign Technology Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the medical device sector with a focus on oral health and orthodontic innovations. The group leverages global industry experience and strategic investment expertise, reflecting its expanding international footprint and emphasis on open, collaborative corporate culture.

Average Trading Volume: 824,490

Technical Sentiment Signal: Buy

Current Market Cap: HK$15.24B

Find detailed analytics on 6699 stock on TipRanks’ Stock Analysis page.